Although topical therapies remain the cornerstone for treating mild psoriasis, biologics that inhibit TNF-α, p40IL-12/23, IL-17, and p19IL-23, as well as oral phosphodiesterase 4 inhibitors, are considered first-line treatment options for moderate to severe plaque psoriasis when traditional drugs such as methotrexate and cyclosporin are contraindicated [7]. Here, IL17A is linked to psoriasis vulgaris.